Dave Madge has extensive experience of small molecule drug discovery gained over a career based in big pharma, academic research roles, and in biotech companies. Dave previously served as VP, Research at Xention Limited and also as its VP, Medicinal Chemistry. Prior to Xention Dave was Chief Operating Officer of NCE Discovery, a specialist chemistry company, and Principal Research Fellow at the Wolfson Institute for Biomedical Research, London, where he specialised in ion channel chemistry.
Dave also served as a Senior Medicinal Chemist at the Wellcome Foundation, Beckenham where he was involved in the development of ion channel blockers for pain, epilepsy, neuro-protection and drug dependency. Dr. Madge has advised and held board positions in a number of start-up companies and holds a PhD in Organic Chemistry from Imperial College, London.